NCT05314517: A reported trial by Kinevant Sciences GmbH
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05314517 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 31, 2022 |
| Completion date | Oct. 16, 2024 |
| Required reporting date | Oct. 16, 2025, midnight |
| Actual reporting date | July 25, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |